Tecomet, Orchid Orthopedic Solutions announce merger agreement

Tecomet and Orchid Orthopedic Solutions have entered into a definitive agreement to merge, bringing together highly complementary capabilities to better serve their global customers, expand reach and support long-term growth.

Tecomet designs, develops, and manufactures medtech and aerospace & defense products. Orchid provides solutions for procedures in major medtech markets in the U.S. and Europe.

The combined company will offer an enhanced portfolio of medtech solutions with a broader, more resilient manufacturing footprint and increased capacity to invest in advanced manufacturing, automation, and capacity expansion aligned with customer demand. They hold the shared goal of serving customers to the highest standard with the combined support of Charlesbank Capital Partners and Nordic Capital, who have been the majority owners of Tecomet and Orchid since 2017 and 2019, respectively.

“We are not just merging two companies – we are committed to an integration that builds on the strengths and heritage of both Tecomet and Orchid,” says Andreas S. Weller, president and CEO of Tecomet. “With complementary technologies, expanded reach, and a dedicated workforce across six countries, we believe the combined company will be better positioned to advance innovation and deliver reliable, high-quality solutions for surgeons worldwide.”

“Strategically, this is a strong fit,” says Nate Folkert, CEO of Orchid. “By combining our manufacturing capabilities, technical expertise, and global footprints, we’re creating a stronger, more competitive organization. Just as importantly, this combination is about long-term stability – building a company that is well equipped to grow, invest, and create opportunity for our people.”

Until the transaction closes, Tecomet and Orchid will continue to operate as separate companies. The merger is subject to regulatory approvals and other customary closing conditions.